CL2014002505A1 - Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos. - Google Patents
Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos.Info
- Publication number
- CL2014002505A1 CL2014002505A1 CL2014002505A CL2014002505A CL2014002505A1 CL 2014002505 A1 CL2014002505 A1 CL 2014002505A1 CL 2014002505 A CL2014002505 A CL 2014002505A CL 2014002505 A CL2014002505 A CL 2014002505A CL 2014002505 A1 CL2014002505 A1 CL 2014002505A1
- Authority
- CL
- Chile
- Prior art keywords
- malignant
- tumors
- flt3
- leukemia
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614274P | 2012-03-22 | 2012-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002505A1 true CL2014002505A1 (es) | 2015-10-02 |
Family
ID=49223277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002505A CL2014002505A1 (es) | 2012-03-22 | 2014-09-22 | Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8877763B2 (es) |
| EP (1) | EP2828259B1 (es) |
| JP (1) | JP6101341B2 (es) |
| KR (1) | KR102011770B1 (es) |
| CN (1) | CN104428298B (es) |
| AU (1) | AU2013235344B2 (es) |
| BR (1) | BR112014023460B1 (es) |
| CA (1) | CA2868156C (es) |
| CL (1) | CL2014002505A1 (es) |
| EA (1) | EA031267B1 (es) |
| ES (1) | ES2694223T3 (es) |
| HK (1) | HK1208453A1 (es) |
| IL (1) | IL234802B (es) |
| IN (1) | IN2014MN02082A (es) |
| MX (1) | MX360912B (es) |
| MY (1) | MY184858A (es) |
| NZ (1) | NZ700283A (es) |
| PL (1) | PL2828259T3 (es) |
| SG (1) | SG11201405942RA (es) |
| TR (1) | TR201816480T4 (es) |
| WO (1) | WO2013142382A1 (es) |
| ZA (1) | ZA201407588B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9212178B2 (en) * | 2013-10-21 | 2015-12-15 | Genosco | Substituted pyrimidine compounds and their use as SYK inhibitors |
| US10065934B2 (en) * | 2014-07-17 | 2018-09-04 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and pharmaceutical uses thereof |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| CN107206005B (zh) | 2014-11-17 | 2021-05-04 | 罗得岛医院 | 纳米材料组成物、合成、与组装 |
| KR20210014212A (ko) * | 2018-06-27 | 2021-02-08 | 주식회사 오스코텍 | Axl 억제제로 사용하기 위한 피리도피리미디논 유도체 |
| KR20200022712A (ko) * | 2018-08-23 | 2020-03-04 | 주식회사 오스코텍 | 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법 |
| KR102230721B1 (ko) * | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN110327347B (zh) * | 2019-08-16 | 2021-06-01 | 陕西科技大学 | G-749在制备抗真菌药物中的应用 |
| TWI759829B (zh) * | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
| AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| KR102440707B1 (ko) | 2022-07-10 | 2022-09-05 | 이우미 | 공장 추천 시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0017075A (pt) * | 2000-01-27 | 2002-11-05 | Warner Lambert Co | Derivados de piridopirimidinona para tratamento de doença neurodegenerativa |
| ATE298751T1 (de) * | 2000-08-31 | 2005-07-15 | Hoffmann La Roche | 7-oxopyridoryrimidine |
| CN1275964C (zh) * | 2000-08-31 | 2006-09-20 | 霍夫曼-拉罗奇有限公司 | 作为细胞增殖抑制剂的7－氧代吡啶并嘧啶 |
| EP2025678A1 (en) * | 2007-08-17 | 2009-02-18 | Oncalis AG | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| JP5634995B2 (ja) * | 2008-08-12 | 2014-12-03 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 化学化合物 |
| US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
| BR112012003661A2 (pt) * | 2009-08-19 | 2017-04-25 | Ambit Biosciences Corp | "compostos de biarila e métodos de uso dos mesmos." |
| US8404677B2 (en) * | 2009-10-29 | 2013-03-26 | Genosco | Kinase inhibitors |
-
2013
- 2013-03-15 AU AU2013235344A patent/AU2013235344B2/en active Active
- 2013-03-15 WO PCT/US2013/032575 patent/WO2013142382A1/en active Application Filing
- 2013-03-15 BR BR112014023460-4A patent/BR112014023460B1/pt active IP Right Grant
- 2013-03-15 ES ES13763998.5T patent/ES2694223T3/es active Active
- 2013-03-15 MX MX2014011354A patent/MX360912B/es active IP Right Grant
- 2013-03-15 EP EP13763998.5A patent/EP2828259B1/en active Active
- 2013-03-15 SG SG11201405942RA patent/SG11201405942RA/en unknown
- 2013-03-15 JP JP2015501823A patent/JP6101341B2/ja active Active
- 2013-03-15 CA CA2868156A patent/CA2868156C/en active Active
- 2013-03-15 IN IN2082MUN2014 patent/IN2014MN02082A/en unknown
- 2013-03-15 US US13/841,827 patent/US8877763B2/en active Active
- 2013-03-15 EA EA201491747A patent/EA031267B1/ru not_active IP Right Cessation
- 2013-03-15 PL PL13763998T patent/PL2828259T3/pl unknown
- 2013-03-15 MY MYPI2014702705A patent/MY184858A/en unknown
- 2013-03-15 KR KR1020147029509A patent/KR102011770B1/ko active IP Right Grant
- 2013-03-15 TR TR2018/16480T patent/TR201816480T4/tr unknown
- 2013-03-15 CN CN201380025782.8A patent/CN104428298B/zh active Active
- 2013-03-15 NZ NZ700283A patent/NZ700283A/en unknown
-
2014
- 2014-09-22 CL CL2014002505A patent/CL2014002505A1/es unknown
- 2014-09-22 IL IL234802A patent/IL234802B/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07588A patent/ZA201407588B/en unknown
-
2015
- 2015-09-16 HK HK15109075.2A patent/HK1208453A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014MN02082A (es) | 2015-08-21 |
| AU2013235344A1 (en) | 2014-10-09 |
| EP2828259A4 (en) | 2015-08-19 |
| US8877763B2 (en) | 2014-11-04 |
| US20130274274A1 (en) | 2013-10-17 |
| HK1208453A1 (en) | 2016-03-04 |
| EA031267B1 (ru) | 2018-12-28 |
| SG11201405942RA (en) | 2014-10-30 |
| MY184858A (en) | 2021-04-27 |
| EP2828259B1 (en) | 2018-08-08 |
| IL234802B (en) | 2018-10-31 |
| KR102011770B1 (ko) | 2019-08-19 |
| CN104428298A (zh) | 2015-03-18 |
| WO2013142382A1 (en) | 2013-09-26 |
| EA201491747A1 (ru) | 2015-10-30 |
| BR112014023460B1 (pt) | 2020-09-01 |
| PL2828259T3 (pl) | 2019-02-28 |
| JP6101341B2 (ja) | 2017-03-22 |
| EP2828259A1 (en) | 2015-01-28 |
| AU2013235344B2 (en) | 2017-03-16 |
| CA2868156A1 (en) | 2013-09-26 |
| NZ700283A (en) | 2016-08-26 |
| MX2014011354A (es) | 2014-12-05 |
| CA2868156C (en) | 2020-07-28 |
| MX360912B (es) | 2018-11-22 |
| TR201816480T4 (tr) | 2018-11-21 |
| ES2694223T3 (es) | 2018-12-19 |
| JP2015510942A (ja) | 2015-04-13 |
| ZA201407588B (en) | 2015-11-25 |
| KR20140144709A (ko) | 2014-12-19 |
| CN104428298B (zh) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002505A1 (es) | Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos. | |
| CL2015001733A1 (es) | Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer. | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
| CL2014002301A1 (es) | Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras. | |
| CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2016000922A1 (es) | Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4 | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| CL2015002394A1 (es) | Inhibidores de histona desmetilasas | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2016001895A1 (es) | Compuestos | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| DOP2015000274A (es) | Compuestos químicos | |
| CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2014001065A1 (es) | Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer. | |
| CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2012002270A1 (es) | Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer. |